Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes

Andrea Pellagatti, Teresa Marafioti, Jennifer C. Paterson, Luca Malcovati, Matteo G. Della Porta, Martin Jädersten, Beena Pushkaran, Tracy I. George, Daniel A. Arber, Sally Killick, Aristoteles Giagounidis, Eva Hellström-Lindberg, Mario Cazzola, James S. Wainscoat, Jacqueline Boultwood

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Lymphoid enhancer-binding factor 1 (LEF1) is a neutrophilic granulopoiesis regulator whose absence is critical in congenital neutropenia. We have shown LEF1 downregulation in the CD34 + cells of the majority of myelodysplastic syndromes (MDS) patients. LEF1 was the most significant differentially expressed gene between early and advanced MDS. Marked LEF1 downregulation was found in 27/32 patients with advanced MDS and in 6/35 patients with early MDS, and was associated with neutropenia. Downregulation of LEF1 mRNA was reflected at the protein level. Immunostaining for CD34/LEF1 may represent a marker of advanced MDS. LEF1 may play a role in the defective maturation of myeloid progenitors in MDS.

Original languageEnglish
Pages (from-to)86-90
Number of pages5
JournalBritish Journal of Haematology
Volume146
Issue number1
DOIs
Publication statusPublished - Jul 2009

Fingerprint

Lymphoid Enhancer-Binding Factor 1
Myelodysplastic Syndromes
Disease Progression
Down-Regulation
Neutropenia
Messenger RNA

Keywords

  • CD34 cells
  • LEF1
  • MDS
  • Neutropenia

ASJC Scopus subject areas

  • Hematology

Cite this

Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. / Pellagatti, Andrea; Marafioti, Teresa; Paterson, Jennifer C.; Malcovati, Luca; Della Porta, Matteo G.; Jädersten, Martin; Pushkaran, Beena; George, Tracy I.; Arber, Daniel A.; Killick, Sally; Giagounidis, Aristoteles; Hellström-Lindberg, Eva; Cazzola, Mario; Wainscoat, James S.; Boultwood, Jacqueline.

In: British Journal of Haematology, Vol. 146, No. 1, 07.2009, p. 86-90.

Research output: Contribution to journalArticle

Pellagatti, A, Marafioti, T, Paterson, JC, Malcovati, L, Della Porta, MG, Jädersten, M, Pushkaran, B, George, TI, Arber, DA, Killick, S, Giagounidis, A, Hellström-Lindberg, E, Cazzola, M, Wainscoat, JS & Boultwood, J 2009, 'Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes', British Journal of Haematology, vol. 146, no. 1, pp. 86-90. https://doi.org/10.1111/j.1365-2141.2009.07720.x
Pellagatti, Andrea ; Marafioti, Teresa ; Paterson, Jennifer C. ; Malcovati, Luca ; Della Porta, Matteo G. ; Jädersten, Martin ; Pushkaran, Beena ; George, Tracy I. ; Arber, Daniel A. ; Killick, Sally ; Giagounidis, Aristoteles ; Hellström-Lindberg, Eva ; Cazzola, Mario ; Wainscoat, James S. ; Boultwood, Jacqueline. / Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. In: British Journal of Haematology. 2009 ; Vol. 146, No. 1. pp. 86-90.
@article{8a65705c751c4c59adfdea0e6613c883,
title = "Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes",
abstract = "Lymphoid enhancer-binding factor 1 (LEF1) is a neutrophilic granulopoiesis regulator whose absence is critical in congenital neutropenia. We have shown LEF1 downregulation in the CD34 + cells of the majority of myelodysplastic syndromes (MDS) patients. LEF1 was the most significant differentially expressed gene between early and advanced MDS. Marked LEF1 downregulation was found in 27/32 patients with advanced MDS and in 6/35 patients with early MDS, and was associated with neutropenia. Downregulation of LEF1 mRNA was reflected at the protein level. Immunostaining for CD34/LEF1 may represent a marker of advanced MDS. LEF1 may play a role in the defective maturation of myeloid progenitors in MDS.",
keywords = "CD34 cells, LEF1, MDS, Neutropenia",
author = "Andrea Pellagatti and Teresa Marafioti and Paterson, {Jennifer C.} and Luca Malcovati and {Della Porta}, {Matteo G.} and Martin J{\"a}dersten and Beena Pushkaran and George, {Tracy I.} and Arber, {Daniel A.} and Sally Killick and Aristoteles Giagounidis and Eva Hellstr{\"o}m-Lindberg and Mario Cazzola and Wainscoat, {James S.} and Jacqueline Boultwood",
year = "2009",
month = "7",
doi = "10.1111/j.1365-2141.2009.07720.x",
language = "English",
volume = "146",
pages = "86--90",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "1",

}

TY - JOUR

T1 - Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes

AU - Pellagatti, Andrea

AU - Marafioti, Teresa

AU - Paterson, Jennifer C.

AU - Malcovati, Luca

AU - Della Porta, Matteo G.

AU - Jädersten, Martin

AU - Pushkaran, Beena

AU - George, Tracy I.

AU - Arber, Daniel A.

AU - Killick, Sally

AU - Giagounidis, Aristoteles

AU - Hellström-Lindberg, Eva

AU - Cazzola, Mario

AU - Wainscoat, James S.

AU - Boultwood, Jacqueline

PY - 2009/7

Y1 - 2009/7

N2 - Lymphoid enhancer-binding factor 1 (LEF1) is a neutrophilic granulopoiesis regulator whose absence is critical in congenital neutropenia. We have shown LEF1 downregulation in the CD34 + cells of the majority of myelodysplastic syndromes (MDS) patients. LEF1 was the most significant differentially expressed gene between early and advanced MDS. Marked LEF1 downregulation was found in 27/32 patients with advanced MDS and in 6/35 patients with early MDS, and was associated with neutropenia. Downregulation of LEF1 mRNA was reflected at the protein level. Immunostaining for CD34/LEF1 may represent a marker of advanced MDS. LEF1 may play a role in the defective maturation of myeloid progenitors in MDS.

AB - Lymphoid enhancer-binding factor 1 (LEF1) is a neutrophilic granulopoiesis regulator whose absence is critical in congenital neutropenia. We have shown LEF1 downregulation in the CD34 + cells of the majority of myelodysplastic syndromes (MDS) patients. LEF1 was the most significant differentially expressed gene between early and advanced MDS. Marked LEF1 downregulation was found in 27/32 patients with advanced MDS and in 6/35 patients with early MDS, and was associated with neutropenia. Downregulation of LEF1 mRNA was reflected at the protein level. Immunostaining for CD34/LEF1 may represent a marker of advanced MDS. LEF1 may play a role in the defective maturation of myeloid progenitors in MDS.

KW - CD34 cells

KW - LEF1

KW - MDS

KW - Neutropenia

UR - http://www.scopus.com/inward/record.url?scp=66949150560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66949150560&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2009.07720.x

DO - 10.1111/j.1365-2141.2009.07720.x

M3 - Article

VL - 146

SP - 86

EP - 90

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -